Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06598800 · ClinicalTrials.gov registry record · Phase 1
Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors
A Phase 1 study of Advanced Solid Tumor, sponsored by BeiGene.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
- 20
- Study locations
NCT06598800: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by BeiGene.
NCT06598800 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by BeiGene. The registered enrollment target is 87 participants, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06598800, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by BeiGene.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in participants with advanced solid tumors.
Primary Outcome
Number of participants with AEs including serious adverse events (SAEs), defined as any unfavorable and unintended sign (including abnormal laboratory findings), symptom, or disease temporally associated with the use of study drugs, whether considered related to study drugs or not as graded by the National Cancer Institute-Common Terminology Criteria for Adverse Events \[NCI CTCAE) V5.0/American Society for Transplantation and Cellular Therapy (ASTCT) for cytokine release syndrome \[CRS\] and im
Conditions Studied
Interventions
- DRUG Drug: BG-T187
- DRUG Other Therapeutic Agents
Study Locations (20)
New South Wales
- Blacktown Cancer and Haematology Centre - Blacktown
- Macquarie University - North Ryde
Hubei
- Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology - Wuhan
- Hubei Cancer Hospital - Wuhan
New Jersey
- Hackensack University Medical Center - Hackensack
Texas
- The University of Texas Md Anderson Cancer Center - Houston
Virginia
- Next Virginia - Fairfax
Wisconsin
- Washington University, St Louis, Division of Oncology - Madison
Victoria
- Cabrini Hospital Malvern - Malvern East
Western Australia
- Linear Clinical Research - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2024-10-18 |
| Est. Completion | 2028-09-30 |
| Phase | Phase 1 |
What NCT06598800 shows while recruiting
NCT06598800 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 87 participants, a relatively small participant target, below the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 2 interventions - of which Drug: BG-T187 is the first listed.
NCT06598800 names 20 study sites across 18 states, led by New South Wales, Hubei, New Jersey.
Frequently Asked Questions
What is clinical trial NCT06598800 about?
NCT06598800 is a clinical study titled "Study of BG-T187 Alone and in Combination With Other Therapeutic Agents in Participants With Advanced Solid Tumors". This is a first-in-human (FIH), Phase 1a/1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-T187 alone and in combination with other therapeutic agents in partic...
What is the current status of trial NCT06598800?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2024-10-18. Estimated completion is 2028-09-30.
What conditions does trial NCT06598800 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06598800?
The interventions under investigation include: Drug: BG-T187 (DRUG), Other Therapeutic Agents (DRUG).
Who is sponsoring clinical trial NCT06598800?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06598800 being conducted?
This trial has 20 study locations across New Jersey, Texas, Virginia, Wisconsin, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06598800's enrollment target sits among peer trials
87 128th of 189 higher than 61 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03292601 · 87 participants · NA
Brace Monitoring for Adolescent Idiopathic Scoliosis (AIS)
- NCT04291105 · 87 participants · Phase 2
Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients
- NCT04565795 · 87 participants · NA
Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy
- NCT05607004 · 87 participants · Phase 2
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI